About: Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models
Creator	Li, Wei Baric, Ralph Gralinski, Lisa Schäfer, Alexandra Peterson, Eric Tseng, Chien-Te Drelich, Aleksandra Dimitrov, Dimiter Leist, Sarah Chen, Chuan Conard, Alex Liu, Xianglei Martinez C#, David Mellors, John Shi, & Zhang, Liyong Zhelev, Doncho
Source	BioRxiv; Medline
abstract	Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We identified panels of fully human monoclonal antibodies (mAbs) from eight large phage-displayed Fab, scFv and VH libraries by panning against the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. One high affinity mAb, IgG1 ab1, specifically neutralized replication competent SARS-CoV-2 with exceptional potency as measured by two different assays. There was no enhancement of pseudovirus infection in cells expressing Fcγ receptors at any concentration. It competed with human angiotensin-converting enzyme 2 (hACE2) for binding to RBD suggesting a competitive mechanism of virus neutralization. IgG1 ab1 potently neutralized mouse ACE2 adapted SARS-CoV-2 in wild type BALB/c mice and native virus in hACE2 expressing transgenic mice. The ab1 sequence has relatively low number of somatic mutations indicating that ab1-like antibodies could be quickly elicited during natural SARS-CoV-2 infection or by RBD-based vaccines. IgG1 ab1 does not have developability liabilities, and thus has potential for therapy and prophylaxis of SARS-CoV-2 infections. The rapid identification (within 6 days) of potent mAbs shows the value of large antibody libraries for response to public health threats from emerging microbes.
has issue date	2020-06-02(xsd:dateTime)
bibo:doi	10.1101/2020.05.13.093088
bibo:pmid	32511413
has license	biorxiv
sha1sum (hex)	c860f30224f42ee6b9588a785877359872de9f26
schema:url	https://doi.org/10.1101/2020.05.13.093088
resource representing a document's title	Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models
has PubMed identifier	32511413
schema:publication	bioRxiv
resource representing a document's body	covid:c860f30224f42ee6b9588a785877359872de9f26#body_text
is schema:about of	named entity 'therapy' named entity 'ab1' named entity 'therapies' named entity 'angiotensin-converting enzyme 2' named entity 'IgG1' named entity 'Fab' named entity 'neutralizes' named entity 'human' named entity 'Author' named entity 'infection' named entity 'infections' named entity 'mAb' named entity 'ab1' named entity 'natural' named entity 'receptor' named entity 'monoclonal antibodies' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'large' named entity 'antibody' named entity 'There' named entity 'ab1' named entity 'sequence' named entity 'One' named entity 'virus' named entity 'mAbs' named entity 'RBD' named entity 'IgG1' named entity 'IgG1' named entity 'wild type' named entity 'receptor binding domain' named entity 'virus' named entity 'antibodies' named entity 'pseudovirus' named entity 'angiotensin-converting enzyme 2' named entity 'animal models' named entity 'infection' named entity 'germline' named entity 'enzyme' named entity 'RBD' named entity 'protein' named entity 'scFv' named entity 'animal models' named entity 'pseudovirus' named entity 'virus' named entity 'neutralizing antibodies' named entity 'receptor' named entity 'RBD' named entity 'non-toxic' named entity 'Ni-NTA' named entity 'Antibody' named entity 'SARS-CoV-2' named entity 'proteome' named entity 'RBD' named entity 'statistical significance' named entity 'SARS-CoV' named entity 'RBD' named entity 'Ni-NTA' named entity 'lower respiratory tract' named entity 'University of Pittsburgh' named entity 'virus' named entity 'receptor' named entity 'spectrophotometrically' named entity 'protein' named entity 'CoV' named entity 'mAb'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software